Helio Genomics develops a multi-analyte blood test for the early detection of cancer, enabling patients to monitor their health with a simple blood draw. This technology addresses the challenge of late-stage cancer diagnosis by providing a convenient and cost-effective screening method, significantly improving treatment outcomes when cancer is detected early.
Funding
$108M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostics are often inconvenient, expensive, and poor predictors of early-stage cancer, leading to late diagnoses and reduced treatment effectiveness. Many available tests require invasive procedures, such as mammograms and colonoscopies, creating barriers to regular screening and early detection.
Solution
Helio Genomics is developing multi-analyte blood tests leveraging an AI-driven platform to detect cancer early, when treatment is most effective. Their approach focuses on identifying novel biomarkers and cell-free DNA (cfDNA) methylation patterns through a simple blood draw, making cancer screening more accessible and convenient. By evaluating cfDNA methylation patterns across nearly 30 genes and measuring key proteins, Helio's tests aim to improve the accuracy of early-stage cancer detection. This non-invasive method enables more frequent monitoring and can be easily integrated into routine check-ups, improving patient outcomes and reducing healthcare costs.
Target Audience
The primary target audience includes individuals at high risk for cancer, physicians, and healthcare providers seeking accessible, accurate, and convenient early cancer detection methods.
Features
- Multi-analyte approach evaluating cell-free DNA (cfDNA) methylation patterns across nearly 30 genes
- Measures key proteins to improve the accuracy of detecting hepatocellular carcinoma (HCC)
- AI-driven platform for identifying signature biomarkers
- Non-invasive blood test requiring only a simple blood draw
- High specificity (91%) and high sensitivity (76%) in detecting early-stage (stage I and II) HCC for HelioLiver test